Research Projects & Grants

For Profit Organization

  • A Multicenter, Prospective, Open label, Randomized Controlled Clinical Trial to Compare the Safety and Effectiveness of the VitaSmart™ Liver Machine Perfusion System with Static Cold Storage for Organ Preservation Prior to Liver Transplantation BTL-2020-01 vs - Version 4.0 dated Sept. 23, 2021, Role: Investigator, Bridge to Life, Ltd, (12/2023 - 08/2024) Status: Completed
  • Post-marketing requirement study to evaluate the safety of Octaplas™ versus plasma in patients undergoing orthotopic liver transplantation with special emphasis on hyperfibrinolysis, Role: Investigator, Octapharma, (06/2018 - 06/2019) Status: Completed
  • A 24 month, multicenter,randomized, open-label safety and efficacy study of concentration-controlled everolimus with reduced calcineurin inhibitor vs mycophenolate with standard calcineurin inhibitor in denovo renal transplant- advancing renal transplant efficacy and safety outcomes with an eveRolimus- based regimen (TRANSFORM, Jan 2015), Role: Investigator, Novartis Pharmaceuticals Corporation, (02/2018 - 02/2019) Status: Completed
  • A prospective observational trial to evaluate the correlation of T-SPOT® response to CMV infection and T cell-mediated acute graft rejection. The PROTECT Study (PROTECT, May 2015), Role: PI, Oxford Immunotec, (07/2017 - 07/2018) Status: Completed
  • A prospective, single-blind, randomized, phase III study to evaluate the safety and efficacy of fibrin sealant grifols (FS Grifols) as an adjunct to hemostasis during parenchymous tissue open surgeries (Protocol IG1102 version 2.1: 24 October 2012), Role: Investigator, Instituto Grifols, S.A., (03/2016 - 03/2017) Status: Completed
  • A phase 3, double-blind, double-dummy, multi-center, prospective, randomized study of the efficacy and safety of LCP-Tacro™ tablets, once daily, compared to Prograf® capsules, twice daily, in combination with mycophenolate mofetil for the prevention of acute allograft rejection in De Novo adult kidney transplant recipients (protocol LCP-Tacro 3002 version 3.0 September 30, 2010), Role: PI, LifeCycle Pharma A/S, (10/2013 - 10/2014) Status: Completed
  • A phase 2, randomized, open-label, parallel group, multi-center study to assess the safety and efficacy of alefacept in de novo kidney transplant recipients, Role: PI, Astellas Pharma US, Inc., (01/2011 - 01/2012) Status: Completed
  • A phase IV, non interventional, multi-center, open-label, prospective, observational study of the safety, effectiveness, tolerability and compliance of immunosuppressive regimen using mycophenolic acid to treat de novo renal transplant patients in routine clinical practice, Role: Investigator, Novartis Pharmaceuticals Corporation, (05/2010 - 05/2011) Status: Completed
  • A Phase III, randomized, open-label, comparative, multi-center study to assess the safety and efficacy of Prograf (tacrolimus)/MMF, modified release (MR) tacrolimus/MMF and neoral (cyclosporine)/MMF in de novo kidney transplant recipients, Role: Investigator, Fujisawa, (02/2009 - 02/2010) Status: Completed
  • A prospective, randomized, multicenter, double-blind study of early corticosteroid cessation vs. long term maintenance corticosteroid therapy with Pograf and CellCept in primary renal transplant recipients, Role: Investigator, Fujisawa, (08/2007 - 08/2008) Status: Completed

Internal

  • The role of B cells in kidney allograft dysfunction (B cell 3/1/2014), Role: Investigator, LLU Transplantation Institute, (06/2022 - 06/2023) Status: Completed
  • Hematologic and Immune Cell Ratios in the Prediction of Outcomes After Solid Abdominal Organ Transplantation, Role: Investigator, LLU Dept. of Surgery, (07/2021) Status: Approved
  • Highly Suppressive Regulatory T Cell as a Biomarker for Immunologically Relevant Delayed/Slow Graft Function after Kidney Transplantation, Role: Investigator, LLU Dept. of Surgery, (10/2020) Status: Approved
  • Outcomes of kidney transplantation with arterial reconstruction from living donors, Role: Investigator, LLU Transplantation Institute, (04/2008) Status: Completed
  • Clinical outcomes of induction therapies in renal transplant patients, Role: Investigator, LLU Transplantation Institute, (12/2007 - 12/2015) Status: Completed
  • Liver transplantation in the presence of portal vein thrombosis, Role: Investigator, LLU Thyroid Research Fund, (10/2007) Status: Completed
  • Hand-assisted laparoscopic donor nephrectomy, Role: Investigator, LLU Dept. of Surgery, (08/2007) Status: Completed

Non-Profit Organization

  • Integration of donor-derived cell-free DNA with HLA-DR+TNFR2+ regulatory T cell in the prediction of acute rejection and graft function after kidney transplantation, Role: Investigator, American Society of Transplant Surgeons, (08/2024 - 08/2025) Status: Approved
  • Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppresion Trial (BENEFIT), Role: PI, Bristol-Myers Squibb Foundation, Inc., (01/2010 - 01/2011) Status: Completed
  • Belatacept evaluation of nephroprotection and efficacy as first-line immunosuppression trial - extended criteria donors, Role: Investigator, Bristol-Myers Squibb Foundation, Inc., (06/2006 - 06/2007) Status: Completed